NPCE
NeuroPace, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Strong sell
-56/100
Last price
12.67
▼ 0.55 (4.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
13.22
Day high
13.38
Day low
12.66
Volume
82.99K
Market cap
$434.89M
P/E (TTM)
—
52W range
9.22 – 19.60
Trailing performance
Returnvs SPY
1W
-9.11%
-11.1%
1M
-14.97%
-16.1%
3M
-24.49%
-29.0%
6M
-12.68%
-30.9%
YTD
-17.94%
-32.2%
1Y
+16.03%
-0.4%
3Y
+30.22%
-52.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NPCE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.53M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 18, 26 | FISCHER FRANK M Director |
STOCK | 1.47K | $22.93K | Direct |
| Jun 18, 26 | GEIGER URI Director |
STOCK | 789 | $12.33K | Direct |
| Jun 18, 26 | KUMAR RAKHI Director |
STOCK | 989 | $15.46K | Direct |
| Jun 5, 26 | FISCHER FRANK M Director |
STOCK | 2.89K | $0 | Direct |
| Jun 5, 26 | HUENNEKENS R SCOTT Director |
STOCK | 2.89K | $0 | Direct |
| Jun 5, 26 | GEIGER URI Director |
STOCK | 2.89K | $0 | Direct |
| Jun 5, 26 | ANDRADE LISA MALDEN Director |
STOCK | 2.89K | $0 | Direct |
| Jun 5, 26 | KUMAR RAKHI Director |
STOCK | 2.89K | $0 | Direct |
| Jun 5, 26 | RYAN RENEE Director |
STOCK | 2.89K | $0 | Direct |
| May 15, 26 | WILLIAMS PATRICK F Chief Financial Officer |
STOCK | 16.82K | $0 | Direct |
| May 15, 26 | BECKER JOEL Chief Executive Officer |
STOCK | 45.88K | $0 | Direct |
| May 15, 26 | MORRELL MARTHA J Officer |
STOCK | 5.46K | $0 | Direct |
| Mar 20, 26 | LACOB JOSEPH S Director |
STOCK | 865 | $11.24K | Direct |
| Mar 20, 26 | FISCHER FRANK M Director |
STOCK | 1.83K | $23.74K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BECKER JOEL |
Chief Executive Officer | 142.82K | Stock Award(Grant) |
FISCHER FRANK M |
Director | 599.53K | Stock Award(Grant) |
GEIGER URI |
Director | 4.45M | Stock Award(Grant) |
KUHN REBECCA |
Chief Financial Officer | 136.59K | Stock Award(Grant) |
KUMAR RAKHI |
Director | 23.04K | Stock Award(Grant) |
LACOB JOSEPH S |
Director | 366.48K | Stock Award(Grant) |
MORRELL MARTHA J |
Officer | 52.74K | Stock Award(Grant) |
ORBIMED ADVISORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
RYAN RENEE |
Director | 2.89K | Stock Award(Grant) |
WILLIAMS PATRICK F |
Chief Financial Officer | 68.67K | Stock Award(Grant) |
Fundamentals
Market cap$434.89M
Enterprise value$453.12M
Revenue (TTM)$106.99M
Gross profit$82.79M
EBITDA$-11.88M
Net income$-16.17M
EPS (TTM)$-0.57
Free cash flow$-2.63M
Total cash$51.70M
Total debt$69.93M
Book value / share$0.35
Shares outstanding34.32M
Float25.52M
Short % of float3.21%
Dividend yield0.00%
Beta (5Y)1.87
Valuation & profitability ratios
Trailing P/E—
Forward P/E-58.26
PEG ratio—
Price / sales—
Price / book36.51
EV / revenue4.24
EV / EBITDA-38.15
Gross margin77.38%
Operating margin-22.53%
Profit margin-17.86%
Return on equity-103.27%
Return on assets-7.47%
Debt / equity588.50
Current ratio4.94
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $99.99M | $79.91M | $65.42M | $45.52M | +25.1% |
| Operating revenue | $99.99M | $79.91M | $65.42M | $45.52M | +25.1% |
| Cost of revenue | $22.77M | $20.82M | $17.30M | $13.03M | +9.3% |
| Gross profit | $77.22M | $59.09M | $48.12M | $32.49M | +30.7% |
| Research & development | $27.89M | $23.65M | $20.78M | $21.95M | +17.9% |
| Selling, general & admin | $65.67M | $57.10M | $54.52M | $51.34M | +15.0% |
| Total operating expense | $93.56M | $80.76M | $75.30M | $73.29M | +15.9% |
| Operating income | -$16.34M | -$21.67M | -$27.17M | -$40.79M | +24.6% |
| Net interest income | -$4.64M | -$5.77M | -$5.47M | -$5.95M | +19.6% |
| Pre-tax income | -$21.46M | -$27.14M | -$32.96M | -$47.08M | +20.9% |
| Net income | -$21.46M | -$27.14M | -$32.96M | -$47.08M | +20.9% |
| Net income to common | -$21.46M | -$27.14M | -$32.96M | -$47.08M | +20.9% |
| Basic EPS | -0.66 | -0.93 | -1.27 | -1.91 | +29.0% |
| Diluted EPS | -0.66 | -0.93 | -1.27 | -1.91 | +29.0% |
| EBIT | -$14.01M | -$18.34M | -$24.44M | -$39.55M | +23.6% |
| EBITDA | -$12.06M | -$16.57M | -$22.83M | -$36.57M | +27.2% |
| Basic shares | 32.72M | 29.13M | 25.85M | 24.59M | +12.3% |
| Diluted shares | 32.72M | 29.13M | 25.85M | 24.59M | +12.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $21.69M | $13.43M | $18.06M | $6.61M | +61.5% |
| Cash & short-term investments | $61.06M | $52.76M | $66.45M | $77.41M | +15.7% |
| Accounts receivable | $14.68M | $12.85M | $12.31M | $7.48M | +14.2% |
| Inventory | $16.90M | $13.38M | $11.21M | $9.71M | +26.3% |
| Total current assets | $94.07M | $81.34M | $92.72M | $97.71M | +15.7% |
| Property, plant & equipment | $11.26M | $12.89M | $14.41M | $15.90M | -12.7% |
| Total assets | $105.56M | $94.65M | $107.65M | $114.11M | +11.5% |
| Total current liabilities | $17.81M | $15.16M | $16.23M | $10.98M | +17.5% |
| Long-term debt | $58.88M | $59.52M | $56.95M | $52.91M | -1.1% |
| Total debt | $70.84M | $73.34M | $72.39M | $69.77M | -3.4% |
| Total liabilities | $86.53M | $86.63M | $87.00M | $79.33M | -0.1% |
| Retained earnings | -$552.41M | -$530.95M | -$503.81M | -$470.85M | -4.0% |
| Shareholder equity | $19.03M | $8.01M | $20.65M | $34.78M | +137.5% |
| Working capital | $76.26M | $66.18M | $76.49M | $86.74M | +15.2% |
| Net tangible assets | $19.03M | $8.01M | $20.65M | $34.78M | +137.5% |
| Shares issued | 33.57M | 30.15M | 27.82M | 25.05M | +11.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$21.46M | -$27.14M | -$32.96M | -$47.08M | +20.9% |
| Depreciation & amortisation | $1.95M | $1.77M | $1.60M | $2.99M | +10.1% |
| Stock-based compensation | $11.09M | $10.28M | $9.56M | $8.35M | +7.8% |
| Change in working capital | -$4.01M | -$5.45M | -$2.48M | -$4.79M | +26.4% |
| Operating cash flow | -$11.01M | -$17.95M | -$19.70M | -$36.87M | +38.7% |
| Capital expenditure | -$332.00K | -$306.00K | -$173.00K | -$603.00K | -8.5% |
| Investing cash flow | -$332.00K | $8.99M | $23.03M | $23.80M | -103.7% |
| Share buybacks | -$49.55M | $0 | — | — | — |
| Financing cash flow | $19.60M | $4.33M | $8.13M | $490.00K | +353.0% |
| Free cash flow | -$11.34M | -$18.25M | -$19.87M | -$37.47M | +37.9% |
| End cash position | $21.81M | $13.55M | $18.18M | $6.73M | +61.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $22.83M | $22.07M | $26.59M | $27.35M | $19.50M | +3.4% |
| Operating revenue | $22.83M | $22.07M | $26.59M | $27.35M | $19.50M | +3.4% |
| Cost of revenue | $3.92M | $4.02M | $6.01M | $6.19M | $3.29M | -2.5% |
| Gross profit | $18.91M | $18.05M | $20.58M | $21.17M | $16.21M | +4.8% |
| Research & development | $6.90M | $7.19M | $7.03M | $6.58M | $6.84M | -4.0% |
| Selling, general & admin | $17.15M | $16.43M | $15.32M | $17.19M | $17.56M | +4.4% |
| Total operating expense | $24.05M | $23.62M | $22.34M | $23.77M | $24.40M | +1.8% |
| Operating income | -$5.14M | -$5.57M | -$1.77M | -$2.60M | -$8.19M | +7.6% |
| Net interest income | -$1.02M | -$956.00K | -$962.00K | -$978.00K | -$1.34M | -6.3% |
| Pre-tax income | -$6.20M | -$6.69M | -$2.73M | -$3.50M | -$10.02M | +7.3% |
| Net income | -$6.20M | -$6.69M | -$2.73M | -$3.50M | -$8.65M | +7.3% |
| Net income to common | -$6.20M | -$6.69M | -$2.73M | -$3.50M | -$8.65M | +7.3% |
| Basic EPS | -0.18 | -0.20 | -0.08 | -0.11 | -0.26 | +10.0% |
| Diluted EPS | -0.18 | -0.20 | -0.08 | -0.11 | -0.26 | +10.0% |
| EBIT | -$4.66M | -$5.17M | -$1.13M | -$1.85M | -$7.96M | +9.8% |
| EBITDA | -$4.13M | -$4.66M | -$607.00K | -$1.36M | -$7.48M | +11.3% |
| Basic shares | 34.10M | 33.72M | 33.39M | 33.13M | 32.86M | +1.1% |
| Diluted shares | 34.10M | 33.72M | 33.39M | 33.13M | 32.86M | +1.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.54M | $14.78M | $21.69M | $20.65M | $22.86M | -15.2% |
| Cash & short-term investments | $51.70M | $53.98M | $61.06M | $60.01M | $62.14M | -4.2% |
| Accounts receivable | $14.93M | $14.79M | $14.68M | $14.94M | $13.55M | +1.0% |
| Inventory | $18.11M | $16.69M | $16.90M | $18.14M | $16.35M | +8.5% |
| Total current assets | $86.19M | $86.98M | $94.07M | $95.33M | $93.74M | -0.9% |
| Property, plant & equipment | $10.46M | $10.96M | $11.26M | $11.68M | $12.16M | -4.6% |
| Total assets | $96.99M | $98.90M | $105.56M | $107.25M | $106.11M | -1.9% |
| Total current liabilities | $17.43M | $16.17M | $17.81M | $19.61M | $17.14M | +7.8% |
| Long-term debt | $59.01M | $59.02M | $58.88M | $58.75M | $58.62M | -0.0% |
| Total debt | $69.93M | $70.46M | $70.84M | $71.18M | $71.52M | -0.8% |
| Total liabilities | $85.11M | $84.44M | $86.53M | $88.74M | $86.68M | +0.8% |
| Retained earnings | -$565.30M | -$559.10M | -$552.41M | -$549.69M | -$546.19M | -1.1% |
| Shareholder equity | $11.88M | $14.45M | $19.03M | $18.52M | $19.44M | -17.8% |
| Working capital | $68.76M | $70.81M | $76.26M | $75.72M | $76.60M | -2.9% |
| Net tangible assets | $11.88M | $14.45M | $19.03M | $18.52M | $19.44M | -17.8% |
| Shares issued | 34.28M | 33.91M | 33.57M | 33.28M | 33.04M | +1.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$6.20M | -$6.69M | -$2.73M | -$3.50M | -$8.65M | +7.3% |
| Depreciation & amortisation | $530.00K | $513.00K | $522.00K | $487.00K | $477.00K | +3.3% |
| Stock-based compensation | $2.30M | $2.28M | $2.61M | $2.63M | $3.23M | +1.1% |
| Change in working capital | -$795.00K | -$2.39M | -$63.00K | -$1.67M | $2.09M | +66.7% |
| Operating cash flow | -$3.90M | -$5.90M | $506.00K | -$1.94M | -$2.09M | +33.8% |
| Capital expenditure | -$125.00K | -$117.00K | -$97.00K | -$30.00K | -$168.00K | -6.8% |
| Investing cash flow | -$125.00K | -$117.00K | -$97.00K | -$30.00K | -$168.00K | -6.8% |
| Share buybacks | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $1.18M | -$166.00K | $635.00K | -$235.00K | -$1.91M | +808.4% |
| Free cash flow | -$4.03M | -$6.02M | $409.00K | -$1.97M | -$2.25M | +33.1% |
| End cash position | $12.78M | $15.63M | $21.81M | $20.77M | $22.98M | -18.2% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
12.50
-1.3% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
-21.9%
Calls bid over puts
Call volume
26
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
15.00
0 contracts
Heaviest put OI
12.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.19 | -0.18 | +5.6% |
| Mar 2026 | -0.23 | — | — |
| Dec 2025 | -0.15 | -0.08 | +48.1% |
| Sep 2025 | -0.19 | -0.11 | +43.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.09 | 8 | $27.12M | -0.9% |
| Next quarter | -0.07 | 8 | $28.39M | +6.8% |
| Current year | -0.43 | 9 | $100.31M | +0.3% |
| Next year | -0.22 | 9 | $122.43M | +22.0% |
Analyst targets & ownership
Mean target$20.00
High target$22.00
Low target$18.00
Implied upside57.85%
Analyst count10
ConsensusNONE
Strong buy / Buy1 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders4.47%
Held by institutions97.33%
Institutions holding160
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.58
-6.72% from price
SMA 20
13.94
-9.13% from price
SMA 50
14.20
-10.79% from price
SMA 100
15.14
-16.31% from price
SMA 200
15.29
-17.11% from price
EMA 12
13.54
-6.46% from price
EMA 26
13.94
-9.10% from price
EMA 50
14.32
-11.53% from price
RSI (14)
34.9
Neutral
MACD (12,26,9)
-0.39
Hist -0.15
ATR (14)
0.56
4.46% of price
Realised vol 30D
40.0%
Annualised
Bollinger upper
15.08
20, 2σ
Bollinger lower
12.81
20, 2σ
50 / 200 cross
Death
14.20 vs 15.29
Trend bias
Below 200
-17.11%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.36
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
40.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-34.3%
Peak to trough
Max drawdown 5Y
-92.6%
Peak to trough
ATR 14
0.56
4.46% of price
Beta (reported)
1.87
5Y monthly, from filing
Short interest
Shares short
956.22K
Prior 845.37K
Change vs prior
+13.1%
Shorts adding
% of float
3.21%
Normal
% of shares out
2.79%
Against total outstanding
Days to cover
7.3
Crowded exit
Float
25.52M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 26 | Keybanc | INITIATED | — | Overweight |
| Jul 29, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 23, 26 | Mizuho | INITIATED | — | Outperform |
| May 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 16, 25 | UBS | MAINTAINED | Buy | Buy |
| Dec 10, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Nov 5, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Nov 5, 25 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 13, 25 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| May 28, 25 | HC Wainwright & Co. | INITIATED | — | Buy |
| May 14, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-06-08
Periodic Financial Reports
10-Q · 2026-05-12
Proxy Statements
DEFA14A · 2026-04-21
Corporate Changes & Voting Matters
8-K · 2026-03-03
Periodic Financial Reports
10-Q · 2025-11-04
Periodic Financial Reports
10-Q · 2025-08-12
Headlines
KeyBanc Initiates NeuroPace at Overweight With $18 Price Target
MT Newswires · 19d ago
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
Zacks · 27d ago
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
Zacks · 33d ago
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
Business Wire · 35d ago
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
Business Wire · 37d ago
NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...
GuruFocus.com · 49d ago
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
Zacks · 51d ago
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
Zacks · 51d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.